Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 19/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25354029 | 0.93 | PARG (0.80) | PARG | |
| SCHEMBL19770715 | 0.90 | PARG (1.00) | PARG | |
| SCHEMBL25365721 | 0.88 | PARG (0.69) | PARGTSHRKMT2A | |
| SCHEMBL25364931 | 0.88 | PARG (0.91) | PARG | |
| SCHEMBL25353182 | 0.88 | PARG (0.91) | PARG | |
| SCHEMBL25364337 | 0.87 | PARG (0.81) | PARGTSHRKMT2A | |
| SCHEMBL25363144 | 0.87 | PARG (0.81) | PARGTSHRKMT2A | |
| SCHEMBL25353654 | 0.85 | PARG (0.66) | PARGTSHRKMT2A | |
| SCHEMBL25364507 | 0.85 | PARG (0.83) | PARGTSHRKMT2A | |
| SCHEMBL30485575 | 0.85 | PARG (0.66) | PARGTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346564-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | claimed |
| EP-4479387-A1 | INHIBITORS OF PARG | ARase Therapeutics Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| CN-119013261-A | Inhibitors of PARG | 雅瑞斯医疗公司 | 2024-11-22 | — | — | CN | claimed |
| US-20230265057-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. | 2023-08-24 | — | — | US | claimed |
| WO-2023154913-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20250346564-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12227484-B2 | Inhibitors of PARG | ARASE THERAPEUTICS INC. (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4479387-A1 | INHIBITORS OF PARG | ARase Therapeutics Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-119013261-A | Inhibitors of PARG | 雅瑞斯医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230265057-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265057-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023154913-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154913-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265057-A1 | INHIBITORS OF PARG | PARG, PARN, PLG | PARG 1/4885TSHR 3125/4885KMT2A 493/4885 |
| US-20250346564-A1 | INHIBITORS OF PARG | PARG, PARN, PLG | PARG 1/4885TSHR 3125/4885KMT2A 493/4885 |
| US-12227484-B2 | Inhibitors of PARG | PARG, PARN, PLG | PARG 1/4885TSHR 3125/4885KMT2A 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.